CR5 Stock Chart & Stats
€10.10
-€0.56(-5.86%)
At close: 4:00 PM EDT
€10.10
-€0.56(-5.86%)
Day’s Range― - ―
52-Week Range€8.82 - €29.30
Previous CloseN/A
Volume0.00
Average Volume (3M)225.00
Market Cap
€645.05M
Enterprise Value€569.93
Total Cash (Recent Filing)€8.00K
Total Debt (Recent Filing)€2.54M
Price to Earnings (P/E)―
Beta0.40
Next Earnings
Nov 05, 2026EPS Estimate
-0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.40
Shares Outstanding61,588,074
10 Day Avg. Volume131
30 Day Avg. Volume225
Financial Highlights & Ratios
PEG Ratio0.60
Price to Book (P/B)4.22
Price to Sales (P/S)0.00
P/FCF Ratio-13.27
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€29.84Price Target Upside195.43% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.34
Revenue Forecast (FY)€743.31K
Bulls Say, Bears Say
Bulls Say
Strong Balance Sheet And Low LeverageVery low leverage and a substantial equity base provide financial flexibility to fund clinical development, absorb setbacks and avoid near-term dependence on debt markets, supporting the company’s ability to pursue its pipeline.
Expanded Ownership Of Neuro-ophthalmology PipelineFull ownership can improve long-term economics by reducing prior milestone and royalty obligations while giving Oculis greater control over development, partnering and commercialization of neuroprotective therapies.
Late-stage Pipeline With Regulatory SupportRegistrational-stage assets and expedited regulatory designations may shorten development pathways and improve access to agency guidance, creating meaningful opportunities for future product approval and commercial relevance.
Bears Say
Minimal And Declining Revenue With Deep LossesThe company has not established a meaningful commercial revenue base, so its substantial operating losses remain dependent on pipeline progress and future approvals. Continued losses increase execution risk before products can generate recurring sales.
Persistent Operating And Free Cash Flow BurnOngoing negative cash generation reflects the high cost of clinical development and means financial resources will continue to be consumed. If trials or approvals take longer, the cash runway and funding requirements could deteriorate.
Future Financing And Dilution RiskLarge accumulated losses and continued development spending increase the likelihood of additional capital needs. Equity financing or share-based acquisitions can extend operations but may dilute existing holders and raise the cost of funding.
Oculis Holding News
CR5 FAQ
What was Oculis Holding’s price range in the past 12 months?
Oculis Holding lowest stock price was €8.82 and its highest was €29.30 in the past 12 months.
What is Oculis Holding’s market cap?
Oculis Holding’s market cap is €645.05M.
When is Oculis Holding’s upcoming earnings report date?
Oculis Holding’s upcoming earnings report date is Nov 05, 2026 which is in 61 days.
How were Oculis Holding’s earnings last quarter?
Oculis Holding released its earnings results on Aug 06, 2026. The company reported -€0.171 earnings per share for the quarter, beating the consensus estimate of -€0.414 by €0.243.
Is Oculis Holding overvalued?
According to Wall Street analysts Oculis Holding’s price is currently Undervalued.
Does Oculis Holding pay dividends?
Oculis Holding does not currently pay dividends.
What is Oculis Holding’s EPS estimate?
Oculis Holding’s EPS estimate is -0.43.
How many shares outstanding does Oculis Holding have?
Oculis Holding has 61,588,074 shares outstanding.
What happened to Oculis Holding’s price movement after its last earnings report?
Oculis Holding reported an EPS of -€0.171 in its last earnings report, beating expectations of -€0.414. Following the earnings report the stock price went up 1.97%.
Which hedge fund is a major shareholder of Oculis Holding?
Currently, no hedge funds are holding shares in DE:CR5
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Oculis Holding Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€29.84 (195.43% Upside)
€29.84 (195.43% Upside)
Blogger Sentiment
Bullish
DE:CR5 Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-29.07%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
36.01%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Oculis Holding
Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A key asset in its therapeutic portfolio is OCS-01, a topical formulation of dexamethasone, currently progressing through Phase 3 clinical trials for the management of diabetic macular edema. Additionally, OCS-02, a topically administered biological candidate, is engaged in Phase 2b clinical studies to treat keratoconjunctivitis sicca, commonly known as dry eye disease. The company is also advancing OCS-05, an innovative neuroprotective agent, which targets acute optic neuritis and an array of other neuro-ophthalmic disorders, including glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. This enterprise maintains its headquarters in Zug, Switzerland.
CR5 Stock 12 Month Forecast
Average Price Target
€29.84
▲(195.43% Upside)
Technical Analysis
EyePoint Pharmaceuticals
―
Spyre Therapeutics
―
Praxis Precision Medicines
―
ARS Pharmaceuticals
―
Upstream Bio, Inc.
―